![Page 1: Multimorbidity and polypharmacy in the elderly](https://reader034.vdocument.in/reader034/viewer/2022052501/628afde0a6c2c915d536c46d/html5/thumbnails/1.jpg)
Multimorbidity and polypharmacyin the elderly
Tomasz Grodzicki
Department of Internal Medicine and Geriatrics
Jagiellonian University
![Page 2: Multimorbidity and polypharmacy in the elderly](https://reader034.vdocument.in/reader034/viewer/2022052501/628afde0a6c2c915d536c46d/html5/thumbnails/2.jpg)
![Page 3: Multimorbidity and polypharmacy in the elderly](https://reader034.vdocument.in/reader034/viewer/2022052501/628afde0a6c2c915d536c46d/html5/thumbnails/3.jpg)
Monroe RT. N Engl J Med 1953;249:277-285.
![Page 4: Multimorbidity and polypharmacy in the elderly](https://reader034.vdocument.in/reader034/viewer/2022052501/628afde0a6c2c915d536c46d/html5/thumbnails/4.jpg)
![Page 5: Multimorbidity and polypharmacy in the elderly](https://reader034.vdocument.in/reader034/viewer/2022052501/628afde0a6c2c915d536c46d/html5/thumbnails/5.jpg)
Barnett K, i wsp. Lancet 2012;380(9836):37-43.
Prevalence of chronic diseases in
Scotland
![Page 6: Multimorbidity and polypharmacy in the elderly](https://reader034.vdocument.in/reader034/viewer/2022052501/628afde0a6c2c915d536c46d/html5/thumbnails/6.jpg)
![Page 7: Multimorbidity and polypharmacy in the elderly](https://reader034.vdocument.in/reader034/viewer/2022052501/628afde0a6c2c915d536c46d/html5/thumbnails/7.jpg)
Barnett K, i wsp. Lancet 2012;380(9836):37-43.
Prevalence of chronic diseases in
Scotland
!
![Page 8: Multimorbidity and polypharmacy in the elderly](https://reader034.vdocument.in/reader034/viewer/2022052501/628afde0a6c2c915d536c46d/html5/thumbnails/8.jpg)
Functional limitations ofsubjects with history of
heart failure hospitalisation
![Page 9: Multimorbidity and polypharmacy in the elderly](https://reader034.vdocument.in/reader034/viewer/2022052501/628afde0a6c2c915d536c46d/html5/thumbnails/9.jpg)
Problems with management of
multimorbid patients
Sampalli T, i wsp. Patient Prefer Adherence.2012;6:757-64.
![Page 10: Multimorbidity and polypharmacy in the elderly](https://reader034.vdocument.in/reader034/viewer/2022052501/628afde0a6c2c915d536c46d/html5/thumbnails/10.jpg)
POLSENIOR Results
Polypharmacy in CHF patients :more advanced CHF = more drugs
Cardiovascular drugs:
ACE-I, ARB, Beta-blockers, diuretics, spironolactone, digitalis, ca-blockers, alpha-blockers, other
antihypertensive drugs, nitrates, statins, anticoagulants, antiarrhythmic, antithrombotic, cytoprotective
![Page 11: Multimorbidity and polypharmacy in the elderly](https://reader034.vdocument.in/reader034/viewer/2022052501/628afde0a6c2c915d536c46d/html5/thumbnails/11.jpg)
Adverse Drug Reactions Inpatient Elderly
•Prospective, observational design
ADR in the very elderly (≥80 years old)
Preventability, severity and type of ADR
•560 pts (mean 85 yrs; 63% female)
1 in 8 experienced ADR
Majority serious (69%) some life-threatening(4%)
63% preventable
Tangiisuran et al; J Nutr HealthAgeing.2009
![Page 12: Multimorbidity and polypharmacy in the elderly](https://reader034.vdocument.in/reader034/viewer/2022052501/628afde0a6c2c915d536c46d/html5/thumbnails/12.jpg)
Special Article
Emergency Hospitalizations for Adverse Drug Events in Older Americans
Daniel S. Budnitz, M.D., M.P.H., Maribeth C. Lovegrove, M.P.H., Nadine Shehab, Pharm.D., M.P.H., and Chesley L. Richards, M.D., M.P.H.
N Engl J MedVolume 365(21):2002-2012
November 24, 2011
![Page 13: Multimorbidity and polypharmacy in the elderly](https://reader034.vdocument.in/reader034/viewer/2022052501/628afde0a6c2c915d536c46d/html5/thumbnails/13.jpg)
Rehospitalisations within 30 days in the USA
Jencks SF et al. N Engl J Med 2009;360:1418-1428
![Page 14: Multimorbidity and polypharmacy in the elderly](https://reader034.vdocument.in/reader034/viewer/2022052501/628afde0a6c2c915d536c46d/html5/thumbnails/14.jpg)
Fewer Emergency Readmissions and Better Quality of Life for Older Adults at Risk of
Hospital Readmission:
A Randomized Controlled Trial to Determine the Effectiveness of a
24‐Week Exercise and Telephone Follow‐Up Program
Journal of the American Geriatrics Society Volume 57, Issue 3, pages 395-402, 24 FEB 2009
![Page 15: Multimorbidity and polypharmacy in the elderly](https://reader034.vdocument.in/reader034/viewer/2022052501/628afde0a6c2c915d536c46d/html5/thumbnails/15.jpg)
From: The Care Transitions Intervention: Results of
a Randomized Controlled Trial
Arch Intern Med. 2006;166(17):1822-1828. doi:10.1001/archinte.166.17.1822
Care Transitions Intervention Activities by Pillar and by Stage of Intervention
![Page 16: Multimorbidity and polypharmacy in the elderly](https://reader034.vdocument.in/reader034/viewer/2022052501/628afde0a6c2c915d536c46d/html5/thumbnails/16.jpg)
The Care Transitions Intervention: Results of
a Randomized Controlled Trial
Arch Intern Med. 2006;166(17):1822-1828. doi:10.1001/archinte.166.17.1822
Costs
Rehosptalizations
![Page 17: Multimorbidity and polypharmacy in the elderly](https://reader034.vdocument.in/reader034/viewer/2022052501/628afde0a6c2c915d536c46d/html5/thumbnails/17.jpg)
Special Article
Readmissions, Observation, and the Hospital Readmissions Reduction Program
Rachael B. Zuckerman, M.P.H., Steven H. Sheingold, Ph.D., E. John Orav, Ph.D., Joel Ruhter, M.P.P., M.H.S.A., and Arnold M. Epstein, M.D.
N Engl J MedVolume 374(16):1543-1551
April 21, 2016
![Page 18: Multimorbidity and polypharmacy in the elderly](https://reader034.vdocument.in/reader034/viewer/2022052501/628afde0a6c2c915d536c46d/html5/thumbnails/18.jpg)
Study Overview
• The ACA Hospital Readmissions Reduction Program applies penalties for high readmission rates.
• Among Medicare beneficiaries, rates declined after the ACA went into effect.
• There was no significant association between changes in observation stays and readmissions.
![Page 19: Multimorbidity and polypharmacy in the elderly](https://reader034.vdocument.in/reader034/viewer/2022052501/628afde0a6c2c915d536c46d/html5/thumbnails/19.jpg)
Change in Readmission Rates for Targeted Conditions and Nontargeted Conditions within 30 Days after Discharge.
Zuckerman RB et al. N Engl J Med 2016;374:1543-1551
![Page 20: Multimorbidity and polypharmacy in the elderly](https://reader034.vdocument.in/reader034/viewer/2022052501/628afde0a6c2c915d536c46d/html5/thumbnails/20.jpg)
Caregivers!
![Page 21: Multimorbidity and polypharmacy in the elderly](https://reader034.vdocument.in/reader034/viewer/2022052501/628afde0a6c2c915d536c46d/html5/thumbnails/21.jpg)
Caregiving as a Risk Factor for Mortality: The Caregiver Health Effects Study
JAMA. 1999;282(23):2215-2219. doi:10.1001/jama.282.23.2215
After adjusting for sociodemographic factors (age, sex, race, education, stressful life events) and physical health status (prevalent disease and subclinical disease), participants who were providing care and experiencing caregiver strain had mortality risks that were 63% higher than those whose spouse was not disabled (RR, 1.63; 95% confidence interval [CI], 1.00-2.65).
![Page 22: Multimorbidity and polypharmacy in the elderly](https://reader034.vdocument.in/reader034/viewer/2022052501/628afde0a6c2c915d536c46d/html5/thumbnails/22.jpg)